MedTrace Logo

Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy

NCT05101629 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2025-07-23

No results posted yet for this study

Summary

Patients with advanced HCC, refractory to atezolizumab and bevacizumab /IO-based therapy will be treated with pembrolizumab and lenvatinib. Efficacy of the combination therapy will be assessed by objective reponse rate, progression free survival, overal survival, safety/tolerability.

Conditions

Interventions

DRUG

Pembrolizumab

Pembrolizumab 200 mg, IV, over 30 minutes every 3 weeks

DRUG

Lenvatinib Capsules

Lenvatinib 8 mg for BW \< 60 kg / 12 mg for BW ≥ 60 kg oral, once daily for 3 weeks

Sponsors & Collaborators

  • Medizinische Hochschule Hannover, Germany, Prof. Dr. Arndt Vogel

    collaborator UNKNOWN

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

    lead OTHER

Principal Investigators

  • Salah-Eddin Al-Batran, Prof. Dr. · Institut für Klinische Krebsforschung IKF GmbH

  • Arndt Vogel, Prof. Dr. · Medizinische Hoschschule Hannover

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-11
Primary Completion
2025-06-30
Completion
2025-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05101629 on ClinicalTrials.gov